Costs of Hypereosinophilic Syndrome
Research type
Research Study
Full title
Understanding the Costs of Hypereosinophilic Syndrome (HES) from Patients' and Prescribers' Perspective.
IRAS ID
317738
Contact name
Ravi Jandhyala
Contact email
Sponsor organisation
AstraZeneca UK Limited
Duration of Study in the UK
1 years, 4 months, 27 days
Research summary
Hypereosinophilic Syndrome (HES) is a group of blood disorders that occur when there is a high number of eosinophils, usually greater than 1,500 per mm3. Although Hypereosinophilic Syndrome is considered a rare and heterogeneous group of disorders, its prevalence is unknown. The majority of Hypereosinophilic syndrome diagnosis are in patients aged 20-50 years, with the mean age being around 45 years old. In addition, existing data suggests a predominance of HES in male patients, compared to female, at a ratio of 9:1. While HES has been diagnosed in children, this is very rare.
This observational study will recruit participants to contribute data to the creation of a List of HES costs categories and associated cost values. It will involve a total of 50 participants (25 patients and 25 healthcare professionals), and will be conducted in two phases. Phase one will include the a qualitative interview to elicit the costs categories and cost values from individual participants, and Phase two will involve an online survey. All study participants will give demographic information to provide the context for data analysis.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
22/EM/0229
Date of REC Opinion
6 Oct 2022
REC opinion
Further Information Favourable Opinion